FY2024 EPS Forecast for Organogenesis Raised by Analyst

Organogenesis Holdings Inc. (NASDAQ:ORGO) – Research analysts at Cantor Fitzgerald upped their FY2024 earnings per share estimates for Organogenesis in a research note issued on Wednesday, November 13th. Cantor Fitzgerald analyst R. Osborn now anticipates that the company will earn ($0.06) per share for the year, up from their prior estimate of ($0.17). The consensus estimate for Organogenesis’ current full-year earnings is ($0.12) per share.

Organogenesis (NASDAQ:ORGO) last announced its quarterly earnings data on Tuesday, November 12th. The company reported $0.09 EPS for the quarter, beating the consensus estimate of ($0.02) by $0.11. The company had revenue of $115.18 million for the quarter, compared to the consensus estimate of $109.59 million. Organogenesis had a negative net margin of 1.62% and a negative return on equity of 2.69%. During the same period in the prior year, the firm posted $0.02 EPS.

Organogenesis Price Performance

Shares of ORGO opened at $3.94 on Monday. Organogenesis has a twelve month low of $2.16 and a twelve month high of $4.70. The company has a market capitalization of $522.35 million, a P/E ratio of -64.33 and a beta of 1.60. The firm has a 50 day moving average of $3.02 and a 200 day moving average of $2.83. The company has a quick ratio of 2.42, a current ratio of 3.09 and a debt-to-equity ratio of 0.21.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the business. Captrust Financial Advisors purchased a new position in Organogenesis in the 3rd quarter worth about $36,000. Pallas Capital Advisors LLC purchased a new position in shares of Organogenesis during the second quarter valued at approximately $38,000. Delap Wealth Advisory LLC bought a new position in Organogenesis during the second quarter valued at approximately $40,000. Intech Investment Management LLC bought a new position in Organogenesis during the third quarter valued at approximately $43,000. Finally, Allspring Global Investments Holdings LLC boosted its holdings in Organogenesis by 4,989.9% in the second quarter. Allspring Global Investments Holdings LLC now owns 15,677 shares of the company’s stock worth $44,000 after purchasing an additional 15,369 shares during the last quarter. Hedge funds and other institutional investors own 49.57% of the company’s stock.

Organogenesis Company Profile

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.